Cannabis stocks surge 25% by 2026 Q4

Market overview

With the Trump administration reclassifying cannabis to Schedule III, regulatory barriers will drop sharply, accelerating institutional investment. Major cannabis firms like Green Thumb Industries and Curaleaf will benefit from increased banking access and reduced tax burdens, driving a robust earnings season.

earnings prediction market

Implied probability (Yes)

72%

Source: user-generated

More earnings markets

• Will cash burn exceed $5M in Q4? — 65% Yes
• Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
• Will Nuburu secure emergency financing by Q3 end? — 35% Yes
• Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
• Will KR miss Q4 operating margin guidance? — 65% Yes
• Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
• Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
• Will inventory days decrease below 70 by year-end? — 40% Yes

Browse all earnings markets →